Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas.

Trial Profile

Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2012

At a glance

  • Drugs Bevacizumab (Primary) ; Vandetanib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual end date changed from Jun 2010 to Feb 2011 as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top